middle.news
How Is PYC Therapeutics Advancing Four RNA Drug Programs with $153m Cash?
8:49am on Monday 21st of July, 2025 AEST
•
Biotechnology
Read Story
How Is PYC Therapeutics Advancing Four RNA Drug Programs with $153m Cash?
8:49am on Monday 21st of July, 2025 AEST
Key Points
Dosing underway in Phase 1a/1b trials for Polycystic Kidney Disease
Clinical proof of concept and FDA alignment for Retinitis Pigmentosa type 11
Dose escalation progressing in Autosomal Dominant Optic Atrophy trials
Preclinical data supports Phelan-McDermid Syndrome program moving to human trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE